It inhibited tau aggregation, attracting interest for the treatment of Alzheimer’s disease [240], was a selective agonist of the farnesoid X receptor FXR (EC50: 3.2 μM) [241], and displayed remarkable neuroprotective effects against oxidative injuries by acting as potent activator of nuclear factor erythroid-derived 2-like 2 (NRF2) in PC12 cells [213]. Here, NR1H4 is linked to early-onset autosomal dominant Alzheimer disease.